Clearside Biomedical (NASDAQ:CLSD) Announces Earnings Results, Misses Expectations by $0.10 EPS
Clearside Biomedical (NASDAQ:CLSD – Get Rating) posted its earnings results on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.10), MarketWatch Earnings reports. Clearside Biomedical had a return on equity of 0.33% and a net margin of 0.28%. During the same period in the prior year, the firm earned ($0.13) EPS.
Clearside Biomedical stock traded up $0.05 during mid-day trading on Friday, hitting $1.41. 178,252 shares of the company’s stock traded hands, compared to its average volume of 300,645. The firm has a 50 day simple moving average of $1.99 and a two-hundred day simple moving average of $2.59. Clearside Biomedical has a fifty-two week low of $1.30 and a fifty-two week high of $7.73.
A number of institutional investors have recently made changes to their positions in CLSD. Goldman Sachs Group Inc. acquired a new stake in Clearside Biomedical during the 2nd quarter valued at $82,000. Morgan Stanley lifted its holdings in Clearside Biomedical by 182.1% during the 3rd quarter. Morgan Stanley now owns 806,555 shares of the company’s stock valued at $4,839,000 after purchasing an additional 520,694 shares during the last quarter. Millennium Management LLC lifted its holdings in Clearside Biomedical by 51.7% during the 3rd quarter. Millennium Management LLC now owns 265,472 shares of the company’s stock valued at $1,593,000 after purchasing an additional 90,437 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Clearside Biomedical by 61.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 30,795 shares of the company’s stock valued at $185,000 after purchasing an additional 11,692 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its position in Clearside Biomedical by 1,462,200.0% during the 4th quarter. BNP Paribas Arbitrage SA now owns 14,623 shares of the company’s stock worth $40,000 after buying an additional 14,622 shares during the period. 44.71% of the stock is owned by institutional investors and hedge funds.
CLSD has been the subject of a number of research reports. Wedbush reissued an “outperform” rating and set a $9.00 target price on shares of Clearside Biomedical in a research note on Friday, March 11th. JMP Securities reduced their price target on Clearside Biomedical from $11.00 to $10.00 and set a “market outperform” rating for the company in a research report on Friday, March 11th. StockNews.com initiated coverage on Clearside Biomedical in a research report on Thursday, March 31st. They set a “hold” rating for the company. Zacks Investment Research downgraded Clearside Biomedical from a “buy” rating to a “hold” rating in a research report on Monday, May 2nd. Finally, TheStreet downgraded Clearside Biomedical from a “c” rating to a “d+” rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Clearside Biomedical presently has an average rating of “Buy” and a consensus price target of $9.25.
Clearside Biomedical Company Profile (Get Rating)
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
- Get a free copy of the StockNews.com research report on Clearside Biomedical (CLSD)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded